argenx Announces Positive CHMP Opinion for Subcutaneous : co

Positive opinion based on Phase 3 ADAPT-SC study demonstrating noninferior total IgG reduction at day 29 with subcutaneously (SC) administered...

Related Keywords

Amsterdam , Noord Holland , Netherlands , Iceland , Israel , United States , United Kingdom , Japan , Norway , Liechtenstein , America , Erin Murphy , Anant Murthy , European Commission , Ghent University Hospital , Committee For Medicinal Products Human Use , Ghent University , Immunology Innovation Program , European Medicines Agency , European Union Member States , Medicinal Products , Human Use , General Manager , Union Member States , North America , Brussels Stock Exchange Argx , Argenx Se ,